Literature DB >> 7665985

Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine.

R W Watson1, H P Redmond, J Mc Carthy, D Bouchier-Hayes.   

Abstract

Taurolidine has bactericidal and antilipopolysaccharide properties. It is broken down into the amino acid taurine, which has been shown to modulate intracellular calcium activity, a critical component in the priming and activation of macrophages and polymorphonuclear leukocytes. We hypothesized that taurolidine may function to enhance immune activity in these cells. The aim of this study was to investigate the immunological effects of taurolidine and correlate findings with survival after a septic challenge in a murine model. Study 1: CD-1 mice underwent cecal ligation and puncture, were randomized to receive taurolidine (200 mg/kg body weight/i.p.) or saline control, and studied for end point survival. Study 2: CD-1 mice were randomized to receive taurolidine (200 mg/kg body weight/i.p.) or saline control. Peritoneal macrophages (PM luminal diameters) were assessed for O2-, NO, tumor necrosis factor-alpha (TNF-alpha), CD11b, phagocytosis, and PMN influx. O2-, TNF-alpha, CD11b expression, and phagocytosis were significantly increased in the taurolidine group. Study 3: PM luminal diameters were cultured in vitro +/- 0.5 mg/ml taurolidine and PM luminal diameter antimicrobial function assessed (O2-, NO, TNF-alpha, and phagocytosis). O2-, TNF-alpha, and phagocytosis were significantly increased, whereas NO was reduced. Study 4: PM luminal diameters were also cultured with taurine (0.5 mg/ml). Similar increase in O2-, TNF-alpha, and phagocytosis were identified. Intracellular PM luminal diameter [Ca2+] was also assessed and increases in free, unbound intracellular [Ca2+] occurred after taurine culture. Thus, in addition to its bactericidal and antilipopolysaccharide activity, taurolidine primes PM luminal diameters for enhanced antimicrobial activity and these effects appear mediated by the amino acid taurine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665985     DOI: 10.1002/jlb.58.3.299

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  10 in total

1.  Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice.

Authors:  Jean Albrengues; Mario A Shields; David Ng; Chun Gwon Park; Alexandra Ambrico; Morgan E Poindexter; Priya Upadhyay; Dale L Uyeminami; Arnaud Pommier; Victoria Küttner; Emilis Bružas; Laura Maiorino; Carmelita Bautista; Ellese M Carmona; Phyllis A Gimotty; Douglas T Fearon; Kenneth Chang; Scott K Lyons; Kent E Pinkerton; Lloyd C Trotman; Michael S Goldberg; Johannes T-H Yeh; Mikala Egeblad
Journal:  Science       Date:  2018-09-28       Impact factor: 47.728

Review 2.  Diagnosis and management of catheter-related bloodstream infections in patients on home parenteral nutrition.

Authors:  Ashley Bond; Paul Chadwick; Trevor R Smith; Jeremy M D Nightingale; Simon Lal
Journal:  Frontline Gastroenterol       Date:  2019-02-12

3.  [In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity].

Authors:  L Petrovic; K A Schlegel; J Ries; J Park; E Diebel; S Schultze-Mosgau; J Wiltfang
Journal:  Mund Kiefer Gesichtschir       Date:  2003-02-14

4.  Antimicrobial activity of a novel catheter lock solution.

Authors:  Chirag B Shah; Marc W Mittelman; J W Costerton; Stephen Parenteau; Michael Pelak; Richard Arsenault; Leonard A Mermel
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 5.  Antimicrobial lock therapy in central-line associated bloodstream infections: a systematic review.

Authors:  Matteo Vassallo; Brigitte Dunais; Pierre-Marie Roger
Journal:  Infection       Date:  2015-02-06       Impact factor: 3.553

6.  The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions.

Authors:  Yannick Wouters; Gina R H Mennen; René H M Te Morsche; Hennie M J Roelofs; Geert J A Wanten
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

7.  Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice.

Authors:  Ansgar Michael Chromik; Sebastian Huss; Hayssam Osseili; Adrien Daigeler; Sabine Kersting; Dominique Sülberg; Ulrich Mittelkötter; Thomas Herdegen; Waldemar Uhl; Annette M Müller
Journal:  J Carcinog       Date:  2010-04-16

8.  Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients.

Authors:  Ruediger Stendel; Louis Scheurer; Kathrin Schlatterer; Urs Stalder; Rolf W Pfirrmann; Ingo Fiss; Hanns Möhler; Laurent Bigler
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Short-term treatment with taurolidine is associated with liver injury.

Authors:  René Fahrner; Anika Möller; Adrian T Press; Andreas Kortgen; Michael Kiehntopf; Falk Rauchfuss; Utz Settmacher; Alexander S Mosig
Journal:  BMC Pharmacol Toxicol       Date:  2017-08-11       Impact factor: 2.483

10.  Salvage of Cardiac Implantable Electronic Device Pocket Infection with Skin Erosion in Frail 92-Year-Old.

Authors:  Marzia Giaccardi; Benito Baldauf; Ernest W Lau; Stefan Borov; Hendrik Bonnemeier
Journal:  J Cardiovasc Dev Dis       Date:  2022-03-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.